Prof. Franco LUMACHI (nato a Padova il 25/12/1951)

Transcript

1 Prof. Franco LUMACHI (nato a Padova il 25/12/1951) Università degli Studi di Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG) Via Giustiniani 2, Padova Telefono: / / Fax: flumachi@unipd.it CURRICULUM VITAE AGGIORNATO AL 30/06/2013 1

2 TITOLI DI STUDIO : 1. Laurea in Medicina e Chirurgia: Padova 24/03/1977; 2. Diploma di Specializzazione in Chirurgia Generale: Padova 12/07/1983; 3. Diploma di Specializzazione in Endocrinochirurgia: Verona ; 4. Diploma di Specializzazione in Endocrinologia: Padova 11/12/1990; 5. Laurea in Scienze politiche, Relazioni internazionali e Diritti umani: Padova 18/07/2011. IDONEITÀ: 1. Idoneità Nazionale a Primario di Chirurgia Generale, Roma 1986; 2. Idoneità ad incarico di Direttore Medico, Unità Operativa Complessa Multidisciplinare di Patologia Mammaria, Azienda Ospedaliera di Cremona, Cremona ATTIVITÀ DI STUDIO ALL'ESTERO: 1. Boston (USA): Massachusetts General Hospital, Harvard University, Novembre 1979, C.A. Wang, MD; 2. Lille (Francia): Clinique Chirurgicale, Université de Lille, Aprile 1984, Prof. C. Proye ; 3. Montréal (Canada): Royal Victoria Hospital, McGilles University, Gennaio 1994, L.D. McLean, MD; 4. Strasbourg (Francia): IRCAD-IESE, Febbraio 1997, Prof. J. Marescaux. ATTIVITÀ UNIVERSITARIA: UNIVERSITÀ DEGLI STUDI DI PADOVA: Medico Interno Universitario con Compiti Assistenziali e di cura (MIUCA): dal 01/11/1977 al 13/10/1988; Ricercatore Universitario Confermato, a tempo pieno, Settore scientifico-disciplinare: Chirurgia Generale (MED/18), con anzianità giuridica dall 1/8/1980 ed anzianità economica dal 14/10/1988 al 30/11/2006; Professore universitario di II fascia, a tempo pieno, confermato (SSD MED/18) dal 1/12/2006 a oggi. ATTIVITÀ OSPEDALIERA ED ASSISTENZIALE: Assistente ospedaliero a tempo pieno dal 4/7/1978 al 21/10/1985; Aiuto ospedaliero e Dirigente medico di I livello a tempo pieno dal 22/10/1985 al 14/ ; Ricercatore Universitario con mansioni assistenziali a tempo pieno dal 15/10/1988 al 31/10/1993; Attribuzione mansioni di Aiuto a tempo pieno ai fini assistenziali (Art. 102, DPR 382/1980) dall 1/11/1993 Incarico di S.S. Senologia, Azienda Ospedaliera di Padova (DG /5/2006) dal 2004 al 2007; Incarico di Dirigente sostituto del Direttore di Struttura Complessa (Art. 18 del C.C.N.L. 1998/1 e 8/6/2000) dal 2001 al 2008 (Primo DG: 346 del 31/5/2001); Tutore-valutatore per l Esame di Stato abilitante per la professione di Medico-Chirurgo ( ); Componente eletto del Consiglio dei Sanitari dell Azienda ospedaliera di Padova, quinquennio ATTIVITÀ OPERATORIA (10/1988-2/2008, come da elenco a parte): 2024 interventi chirurgici, di cui 862 come primo operatore. Oltre 1000 interventi ambulatoriali. ATTIVITÀ DIDATTICA: UNIVERSITÀ DEGLI STUDI DI PADOVA CORSO DI LAUREA MAGISTRALE IN MEDICINA E CHIRURGIA: MATERIE DI INSEGNAMENTO: Clinica Chirurgica Generale e Terapia Chirurgica, Esercitazioni teorico-pratiche, AA Chirurgia Generale, C.I. Metodologia Clinica, IV anno, I semestre, sede di Padova, Corso 2, AA , , , , , , , , , , , , (Corsi 1 e 2). Chirurgia Generale, C.I. Metodologia Clinica, IV anno, I semestre, sede di Treviso, AA , , , , Chirurgia Generale, C.I. Semeiotica Pratica e Propedeutica Clinica, IV anno, II semestre, sede di Treviso, AA Chirurgia Generale (DM 509/99), VI anno, I semestre, sede di Treviso, AA Chirurgia Generale (DM 509/99), V anno, II semestre, sede di Treviso, AA Chirurgia Endocrina, C.I. Specialità Medico-chirurgiche 1, IV anno, I semestre, sede di Padova, Corso 1, AA

3 Chirurgia Endocrina, C.I. Specialità Medico-chirurgiche 2, IV anno, I semestre, sede di Padova, Corso 1, AA Chirurgia d urgenza, C.I. Emergenze Medico-chirurgiche, IV anno, II semestre, sede di Treviso, AA , Titolare del Corso di Senologia, V anno, II semestre, sede di Padova, Corsi 1 e 2, AA , , , , , Titolare del Corso di Senologia, V anno, II semestre, sede di Treviso, AA , , , , Titolare del Corso di Fisiopatologia Chirurgica delle Ghiandole Endocrine, IV anno, I semestre, sede di Padova, Corsi 1 e 2, AA , , Titolare del Corso di Fisiopatologia Chirurgica delle Ghiandole Endocrine, IV anno, I semestre, sede di Treviso, AA , Titolare del Corso di Fisiopatologia Chirurgica delle Ghiandole Endocrine, III anno, I semestre, sede di Padova, Corsi 1 e 2, AA CORSO DI LAUREA TRIENNALE IN INFERMIERISTICA (DM 270): MATERIE DI INSEGNAMENTO: Chirurgia d Urgenza, C16, III anno, I semestre, Sede Conegliano (TV), AA Chirurgia d Urgenza, C16, III anno, I semestre, Sede Mestre (VE), AA SCUOLE DI SPECIALIZZAZIONE (SCUOLA DI MEDICINA E CHIRURGIA): MATERIE DI INSEGNAMENTO: Scuola di Specializzazione in Chirurgia d Urgenza e di Pronto Soccorso: AA e : Chirurgia di piccolo pronto soccorso, I anno (20 ore) AA , : Chirurgia di piccolo pronto soccorso, I anno (50 ore). AA e : Chirurgia generale, I anno (10 ore). Scuola di Specializzazione in Chirurgia Plastica e Ricostruttiva: AA , , , : Chirurgia generale, IV anno (10 ore). Pu Scuola di Specializzazione in Chirurgia Generale: AA , , , : Endocrinochirurgia, III anno (10 ore) AA , , , : Anatomia chirurgica, I anno (50 ore) AA : Microchirurgia, III anno (30 ore). Scuola di Specializzazione in Chirurgia Generale I (Vecchio ordinamento): AA , , , , : Anatomia chirurgica, I anno (30 ore) AA , , , , , , , , : Endocrinochirurgia, IV anno (20 ore). AA , , , : Tecniche chirurgiche complementari in chirurgia oncologica, VI anno (30 ore) AA , : Chirurgia vascolare, V anno (20 ore). È Segretario della Scuola di Specializzazione in Chirurgia Generale dall AA ad oggi. Scuola di Specializzazione in Chirurgia Generale (Nuovo ordinamento): AA (Coorte 17/5/2010), AA (Coorte 30/6/2011), AA (Coorte 5/7/2012): Clinica chirurgica I. Obiettivi formativi: Studio delle patologie chirurgiche sotto l aspetto della prevenzione, screening, diagnosi e terapia con riferimento alle patologie del sistema endocrino (II anno, Tronco comune). OSPEDALE CIVILE DI PADOVA Docente di Anatomia umana presso la Scuola di Tecnici di Radiologia Medica, I anno, AA Relatore, Correlatore o Controrelatore di numerose TESI di Laurea Magistrale in Medicina e Chirurgia e di Diploma di Specializzazione in Chirurgia generale. 3

4 DOTTORATI DI RICERCA : Partecipazione al Dottorato di Ricerca Scienze chirurgiche ed implicazioni tecnologiche Ciclo XXIV Partecipazione al Collegio 2009 del Dottorato di Ricerca Indirizzo di epatologia e chirurgia epatobiliare e trapiantologica AA di inizio: , Ciclo XXV. COMMISSARIO DI CONCORSO NAZIONALE UNIVERSITARIO (Legge 219/1998, DPR 117/2000): Università degli Studi di Genova: Componente della Commissione per la Valutazione comparativa di un posto di Ricercatore universitario F08A (DR 2292 del 25/7/2000, GU 66, IV sezione speciale, 25/8/2000); Università degli Studi di Roma Tor Vergata : Componente della Commissione per la Valutazione comparativa di un posto di Ricercatore universitario F08A (DR 0663 del 20/4/2001, GU 34, IV serie speciale, del 27/4/2001). MINISTERO DELL ISTRUZIONE, DELL UNIVERSITÀ E DELLA RICERCA (ROMA): Componente dell Albo dei Revisori per la valutazione dei Programmi di ricerca ministeriale per i Settori dell European Research Council: Endocrinology, Therapies, Diagnostics. Ha ricevuto l incarico dal MIUR, Direzione Generale per lo Sviluppo e la Ricerca di valutare proposte di progetti di ricerca nazionali e di verifica della qualità della ricerca di Atenei italiani (Prot. 202 del 15/7/2009): Revisore di progetti di ricerca per giovani ricercatori (Futuro in Ricerca 2010) MIUR, Direzione Generale della Ricerca, Ufficio V (Prot. 358/RI/V del 14/2/2011); Revisore Progetti di Ricerca 2013 come Esperto incaricato dal MIUR, Direzione Generale per il Coordinamento e lo Sviluppo della Ricerca, Ufficio V (Prot. 562 del 21/01/2013); Esperto Valutatore di Progetti di Ricerca di Interesse Nazionale (PRIN) 2012 (D.M. 28/12/2012 n. 957/Ric); Revisore Valutatore Esterno dell ANVUR (Agenzia Nazionale per la Valutazione del sistema Universitario e della Ricerca), GEV 06 (Gruppo Esperti Valutatori) Progetto VQR (Prot. 456 dell 11/10/2012). COMMISSIONE EUROPEA (BRUXELLES) Esperto revisore programma FP7 Expert Evaluator/Reviewer Cordis Reseach Program of the European Commission. LIFESCIHEALTH e : ATTIVITA ORGANIZZATIVA come SEGRETERIA SCIENTIFICA ( ): 1. 5th International Postgraduate Meeting of Endocrine Surgery: Controversies in Endocrine Surgery, Padova 15-16/6/ Aspetti epidemiologici e clinici dell iperparatiroidismo primitivo, Padova 23/5/ th International Postgraduate Meeting of Endocrine Surgery: Present and future in Endocrine Surgery, Padova 3-4/6/ th International Postgraduate Meeting of Endocrine Surgery: New Trends in Endocrine Surgery, Padova 28-29/6/ th International Postgraduate Meeting of Endocrine Surgery: Updates in Endocrine Surgery, Padova 18/6/ th International Postgraduate Meeting of Endocrine Surgery: New Developments in Endocrine Surgery, Padova 16/6/ Meeting Attualità in tema di patologia tiroidea: Riva del Garda (TN) 24/5/2003 RESPONSABILE DI GRUPPI DI RICERCA: RICERCA ISTITUZIONALE (EX 60%) UNIVERSITÀ DI PADOVA: 1996: Metastasi midollari in pazienti con carcinoma mammario. 1997: L antioncogene p35 e la sua proteina nella patogenesi dei tumori del surrene. 1998: MIB1 e ploidia come fattori prognostici nel carcinoma mammario. 1999: Riduzione della multidrug resistance in colture cellulari MCF : Determinazione dell attività talomerasica nelle neoplasie mammarie. 4

5 2001 (60A /01): Mammoscintigrafia ed FNAB eco-guidato come metodiche non invasive alternative alla biopsia chirurgica nelle lesioni mammarie sospette (60A /02): Cancro della mammella. Ricerca dei fattori di rischio mediante analisi multivariata applicata alla popolazione di un'area urbana (60A /03): Nuovi marker biologici ed altri parametri predittivi di cancro della mammella (60A /04): Utilizzo di nuove tecnologie nel trattamento del carcinoma mammario (60A /05): Qualità di vita dopo interventi demolitivi per cancro della mammella in relazione all utilizzazione di nuove tecniche chirurgiche con approccio multidisciplinare (60A /06): Mammoscintigrafia e cancro della mammella. Analisi delle cause di falsi negativi e correlazione con i principali fattori prognostici che condizionano il decorso clinico della malattia (60A /07): Scintigrafia con 99mTc-sestamibi ed ecografia nello studio preoperatorio dei linfonodi ascellari in pazienti con cancro della mammella (60A /08): Correlazione tra uso di contraccettivi orali e status recettoriale nelle pazienti con carcinoma mammario (60A /09): FNAB eco-guidato e ricerca linfonodo sentinella in pazienti con carcinoma mammario (60A /10): Cancro della mammella: analisi dell incremento di rischio legato alle terapie con estrogeni (60A /11): Ipercalcemia neoplastica e cancro della mammella. Ruolo dei marker plasmatici di rimaneggiamento osseo (60A /12): VEGF come fattore prognostico nelle pazienti con cancro della mammella. COMPONENTE DI GRUPPI DI RICERCA: 1. RICERCHE SANITARIE FINALIZZATE DELLA REGIONE VENETO (VENEZIA) (292/02/90): Prevenzione e trattamento dell iperparatiroidismo primitivo in età geriatrica (490/01/94): Studio diagnostico-terapeutico sui tumori non funzionanti del surrene : Studio epidemiologico e trattamento precoce delle neoplasie surrenaliche 2. RICERCA ISTITUZIONALE (EX 60%) UNIVERSITÀ DI PADOVA: : Immunosorveglianza nella carcinogenesi nella colite ulcerosa (60A ) : La laser terapia del cancro inoperabile del grosso intestino (60A ) : Network citochinico nella pouchite cronica (60A ) : Network citochinico tissutale nella malattia perianale di Crohn (60A ) : Network citochinico tissutale nella malattia perianale di Crohn (proseguimento) e : Laser terapia del cancro inoperabile del grosso intestino II. Proseguimento (60A e 60A ) CONTRIBUTI SCIENTIFICI PERSONALI presentati a Congressi Internazionali e pubblicati ( ) BARCELONA (SPAIN) 6-8 MARCH, th Annual Conference of the European Neuroendocrine Tumor Society (ENETS): a. Chromogranin A, NSE, and 5-hydroxyindolacetic acid measurements in malignant carcinoids (p. 113). b. Prognostic factors affecting outcome in patients with liver resection of neuroendocrine hepatic metastasis. 2. ROME (ITALY) APRIL, European Congress on Osteoporosis and Osteoarthritis & International Osteoporosis Foundation (ECCEO13-IOF): a. Lumbar-spine bone mineral density changes following chemotherapy in women with estrogen receptorpositive breast cancer and lymph node metastasis (OSTEOPOROS INT 2012; 24 S1: 195). b. Invasive breast cancer and risk factors of bone metastasis in women who underwent curative surgery. A retrospective case-control study (OSTEOPOROS INT 2012; 24 S1: 197). c. Relationship between bone serum markers in patients with bone metastases from non-small cell lung carcinoma (OSTEOPOROS INT 2012; 24 S1: 199). d. Cytokeratin positivity in bone marrow cells as predictor of onset of bone metastases in patients with advanced breast cancer (OSTEOPOROS INT 2012; 24 S1: 241). 3. LUGANO (SWITZERLAND), 9-11 MAY, European Multidisciplinary Conference in Thoracic Oncology (EMCTO 13): 5

6 a. Risk factors of lung metastases from advanced invasive ductal carcinoma of the breast (LUNG CANCER 2012; 80 S1: 43). b. Preoperative cefazolin prophylaxis prevents surgical site infection in patients undergoing open and thoracoscopic surgery for lung cancer. A case-control study (LUNG CANCER 2012; 80 S1: 43). c. Serum markers of bone metabolism measurement in patients with breast cancer and lung metastasis (LUNG CANCER 2012; 80 S1: 44). 4. BARCELONA (SPAIN) 3-7 JULY, European Society for Medical Oncology (ESMO) 15th World Congress of Gastrointestinal Cancer: a. Factors affecting survival in patients with colorectal cancer and lung metastases (ANN ONCOL 2012; 24 S4: 107). b. CT-guided fine-needle aspiration cytology and CDX2 immunostaining of pulmonary nodules in patients with colorectal cancer. Preliminary study (ANN ONCOL 2012; 24 S4: 109). c. Prognostic significance of circulating tumor cells in patients with colorectal cancer and liver metastases (ANN ONCOL 2012; 24 S4: 108). d. Occult nodal micrometastases revealed by the mrna C-MET and its significance in patients with recurrent colorectal cancer (ANN ONCOL 2012; 24 S4: 110) BORDEAUX (FRANCE) MARCH, European Congress on Osteoporosis and Osteoarthritis & International Osteoporosis Foundation (ECCEO12-IOF): a. Bone alkaline phosphatase and osteocalcin as markers of osteoporosis in postmenopausal women with breast cancer and bone metastases (OSTEOPOROS INT 2012; 23 S2: 141). b. Association between calcium-regulating hormones PTH, 25(OH)D, IGF-I and BMD in elderly women who were not estrogen or bisphosphonate users (OSTEOPOROS INT 2012; 23 S2: 145). c. Relationship between bone remodeling serum markers and BMD in premenopausal women with advanced breast cancer (OSTEOPOROS INT 2012; 23 S2: 145). d. Usefulness of ICTP and TRACP5b measurement in women with bone metastases from breast carcinoma and severe osteoporosis: preliminary results (OSTEOPOROS INT 2012; 23 S2: 146). e. Early detection of bone metastases from small-cell lung cancer using serum carboxy-terminal (CTX) and aminoterminal (PINP) telopeptide of type-i collagene measurement: preliminary results (OSTEOPOROS INT 2012; 23 S2: 269). 2. VIENNA (AUSTRIA) MARCH, th European Breast Cancer Conference (EBCC8): a. Tartrate-resistant acid phosphatase and C-terminal telopeptide of type I collagen as serum tumor markers in women with bone metastases from breast cancer (EUR J CANCER 2012; 48 S1: 110). b. Flow cytometry analysis of circulating endothelial cells in women with breast cancer (EUR J CANCER 2012; 48 S1: 123). c. Vascular endothelial growth factor as prognostic factor in patients with breast cancer. A multicentric long-term follow up study (EUR J CANCER 2012; 48 S1: 137). d. Prognostic and predictive factors in breast cancer relapse. Long-term retrospective study in a cohort of patients with invasive ductal carcinoma (EUR J CANCER 2012; 48 S1: 138). e. Risk factors of breast cancer relapse. A Case-control study and results of multivariate analysis in a cohort of 348 patients who underwent curative surgery (EUR J CANCER 2012; 48 S1: 142). 3. GENEVA (SWITZERLAND) APRIL, rd European Lung Cancer Conference (ELCC): a. Usefulness of bone resorption markers CTX, TRAP5b, and PINP in patients with non-small cell lung cancer and bone metastases. Preliminary study (J THORAC ONCOL 2012; 7 S: 27). b. Urokinase-type plasminogen activator and inhibitor as prognostic markers in patients with non-small cell lung cancer and lymph node metastases (J THORAC ONCOL 2012; 7 S: 41). c. Prognostic factors for survival of symptomatic patients with malignant pleural effusion who underwent palliative talc pleurodesis (J THORAC ONCOL 2012; 7 S: 78). d. Risk factors for lung metastases from invasive ductal breast carcinoma. A case-control study at five-year follow-up in a population of women who underwent curative surgery (J THORAC ONCOL 2012; 7 S: 88). 4. HOUSTON, TX (USA) JUNE 23-26, The Endocrine Society, 94 th Annual Meeting (ENDO12): Role of monocyte activation markers in patients with localized and metastatic breast cancer. Preliminary results (ENDOCR REV 33 (S3): 233, 2012). 5. BARCELONA (SPAIN) JUNE, European Society for Medical Oncology (ESMO) Conference, 14th World Congress on Gastrointestinal Cancer: 6

7 a. Open and video-assisted thorascoscopic resection of solitary lung metastases in patients with colorectal cancer (ANN ONCOL 2012; 23 S4: 97). b. Talc pleurodesis improves quality of life of patients with advanced colorectal cancer and malignant pleural effusion (ANN ONCOL 2012; 23 S4: 105). c. Carboxy-terminal telopeptide of type I collagene and tartrate-resistant acid phosphate in patients with colorectal cancer and bone metastases (ANN ONCOL 2012; 23 S4: 106). d. Correlation between serum vascular endothelial growth factor (VEGF) and VEGF-1 expression in patients with colorectal cancer. Preliminary results (ANN ONCOL 2012; 23 S4: 107). e. Circulating endothelial cells in patients with colorectal cancer: flow cytometry analysis of cell marker CD146-PE and CD45-FITC (ANN ONCOL 2012; 23 S4: 108). 6. VALENCIA (SPAIN) SEPTEMBER, European Society of Surgical Oncology (ESSO), 32th Biennial Congress: a. Localized and metastatic breast cancer. Role of polymorphonuclear CD64 index measurement as marker of monocyte activation (EUR J SURG ONCOL 2012; 38: 810). b. CD45-FITC and CD146-PE measurement as marker of circulating endothelial cells in patients with colorectal cancer (EUR J SURG ONCOL 2012; 38: 833). c. Usefulness of cathepsin D, Ki-67, and PCNA in patients with colorectal cancer and lymph node metastasis (EUR J SURG ONCOL 2012; 38: 838). 7. VIENNA (AUSTRIA) 28 SEPTEMBER-2 OCTOBER, European Society for Medical Oncology (ESMO), 37th Annual Congress: Prognostic significance of epidermal growth factor receptor overexpression and chromosome 7 polysomy in clear cell renal cell carcinoma (ANN ONCOL 2012; 23 S9: 287) LUGANO (SWITZERLAND) FEBRUARY European Multidisciplinary Conference in Thoracic Surgery (EMCTS): a. Multiplex analysis of a panel of bone remodeling serum markers in patients with bone metastases from lung cancer (LUNG CANCER 2011; 71 S2: 27). b. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small lung carcinoma and bone metastases (LUNG CANCER 2011; 71 S2: 32). c. Short-term results of surgical resection of pulmonary metastases from colorectal and noncolorectal cancers (LUNG CANCER 2011; 71S2: 50). 2. VALENCIA (SPAIN), MARCH, European Congress on Osteoporosis and Osteoarthritis & International Osteoporosis Foundation (ECCEO 10-IOF): a. Bone mineral density in postmenopausal women with hormone receptor-positive breast carcinomas. Preliminary results (OSTEOPOROS INT 2011; 22 S1: 221). b. Automated protein-array chip system for bone turnover markers measurement in pre- and postmenopausal women with osteoporosis (OSTEOPORS INT 2011; 22 S1: 223). c. Postmenopausal women with osteoporosis and risk of breast cancer: a case-control study in a high-risk population (OSTEOPOROS INT 2011; 2 S1: 230). d. Relationship between BMD, osteocalcin, and bone alkaline phosphatase in pre- and postmenopausal women with advanced breast cancer (OSTEOPOROS INT 2011; 2 S1:324). 3. BERLIN (GERMANY) 30 MARCH-3 APRIL, th Annual Meeting of European Association for the Study of the Liver (EASL): Stereotactic body radiotherapy in patients with unresectable hepatocellular carcinoma. Preliminary results and comparison with other palliative treatments (J HEPATOL 2011; 54 S1:259). 4. BOSTON, MA (USA), JUNE 4-7, The Endocrine Society, 93rd Annual Meeting (ENDO 11): Relationship between bone formation markers bone alkaline phosphatase, osteocalcin, and amino-terminal propeptide of type I collagen, and bone mineral density in elderly men (ENDOCR REV 32: P3-139, 2011). 5. BARCELONA (SPAIN), JUNE, European Society for Medical Oncology (ESMO) Conference, 13th World Congress on Gastrointestinal Cancer: a. Recurrence-free survival of patients with liver metastases from colorectal cancer who underwent radiofrequency treatment of surgical margins (ANN ONCOL 2011; 22 S5: 67). b. Usefulness of chromogranin A, neuron-specific enolase, and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids (ANN ONCOL 2011; 22 S5: 70). 7

8 c. Colorectal cancer laboratory screening using a multiplex immunoassay based on automated protein array system for serum tumor markers (ANN ONCOL 2011; 22 S5: 90). d. Relationship between Ki-67 and p53 expression and survival in men with colorectal cancer (ANN ONCOL 2011; 22 S5: 105). 6. STOCKHOLM (SWEDEN), SEPTEMBER, European Multidisciplinary Cancer Congress (ECCO16): a. Risk factors incidence in postmenopausal women with hormone receptor negative/her2 positive and triple negative breast cancer. Preliminary results (EUR J CANCER 2011; 47 S1: 251). b. Relationship between survival, hormone receptor rate, and CA15-3 serum levels in patients with isolated liver metastases from breast cancer (EUR J CANCER 2011; 47 S1: 360) BARCELONA (SPAIN), MARCH, European Breast Cancer Conference (ECCO 7): a. Estrogens exposure as risk of breast cancer in premenopausl women all residing in the same metropolitan area. A case-control study in a cohort of 486 women (EUR J CANCER 2010; 8 S3: 217). b. Previous oral contraceptive use and breast cancer risk among pre- and postmenopausal women. Retrospective study in a cohort of 979 patients (EUR J CANCER 2010; 8 S3: 220). c. Relationship between hormone receptors, MIB-1 index, and serum tumor markers CEA and CA 15-3 in patients with pt1-2 breast cancer (EUR J CANCER 2010; 8 S3: ). 2. BARCELONA (SPAIN), JUNE 24-27, The Academy for Clinical Debates & Controversies in Medicine. 1st International Congress on Controversies in Longevity, Health and Aging (CoLONGY): a. Bone mineral density and oxidative stress markers in postmenopausal women with osteoporosis: a casecontrol study. b. Relationship between arterial blood pressure, calcemia and PTH in postmenopausal patients with primary hyperparathyroidism. 3. BARCELONA (SPAIN), 30 JUNE-3 JULY, European Society for Medical Oncology (ESMO) Conference, 12th World Congress on Gastrointestinal Cancer: a. Molecular markers PCNA, Ki 76, and cathepsin D in patients with colorectal cancer and their relationship with lymph node involvement (ANN ONCOL 2010; 21 S6: 70). b. Usefulness of serum tumor markers CEA, CA 19-9 and CA 72-4 in patients with colorectal cancer and benign colorectal diseases. A retrospective multicentric study (ANN ONCOL 2010; 21 S6: 119). 4. BORDEAUX (FRANCE), SEPTEMBER, th Congress of the European Society of Surgical Oncology (ESSO 15): a. Hormone receptor rate and serum tumor markers CEA and CA 15-3 relationship in patients with confirmed early (pt1) breast cancer (EUR J SURG ONCOL 2010; 36: 857). b. Ursodesoxycholic acid for chemioprevention in patients with ulcerative colitis at risk of developing cancer (EUR J SURG ONCOL 2010; 36: 876). c. Role of C-reactive protein in predicting survival of patients with colorectal cancer (EUR J SURG ONCOL 2010; 36: 882). d. Ultrasound-guided FNA cytology combined with flow cytometry in the diagnosis of suspected or recurrent lymphoma (EUR J SURG ONCOL 2010; 36: 894). e. Radiofrequency after liver resection in primary and metastatic liver tumors (EUR J SURG ONCOL 2010; 36: 897). 5. SHEFFIELD (UK), SEPTEMBER, th International Conference: Cancer-Induced Bone Disease. a. Relationship between serum N-telopeptide and bone alkaline phosphatase and their diagnostic value in patients with breast cancer and bone metastases (BONE 2011; 48: S25). b. Reduced risk of breast cancer in postmenopausal women with osteoporosis. Preliminary results in a high risk metropolitan area: a case-control study (BONE 2011; 48: S26). c. Bone mineral density and bone remodeling markers osteocalcin and alkaline phosphatase in patients with stage IV breast cancer (BONE 2011; 48: S27). 6. ST. GALLEN (SWITZERLAND) DECEMBER 1-3, European Colorectal Congress. Complications in Liver Metastases: Complementary techniques of liver resection in primary and metastatic liver tumors. 8

9 PHOENIX, AZ (USA), MARCH 4-8, Society of Surgical Oncology (SSO), 62nd Annual Cancer Symposium: Image-guided stereotactic radiosurgery for local control of unresectable liver metastases using the CyberKnife robotic system. Preliminary results (ANN SURG ONCOL 2009; 16 S1: 85). 2. NEW YORK, NY (USA), MARCH 12-14, NY Academy of Sciences: Hypoxia and Consequences: from Molecule to Malady: a. Relationship between hypoxemia, age, and body mass index in patients with extremely severe obesity undergoing bariatric surgery (IN VIVO 2010; 24: 775). b. Improvement of hypoventilation syndrome and hypoxemia in morbidly obese patients following laparoscopic gastric by-pass (IN VIVO 2010; 24: 329). 3. LONDON (UK), MAY 16-20, th European Congress on Menopause (EMAS 8). a. Relationship between preoperative serum CEA and CA 15-3 and risk of breast cancer recurrence in postmenopausal elderly women (MATURITAS 2009; 63 S1: 49). b. Oral contraceptive use and hormone replacement therapy together as a risk of breast cancer among postmenopausal women (MATURITAS 2009; 63 S1: 50). c. Bone mineral densitometry and quantitative bone ultrasound in evaluating bone changes in postmenopausal women with severe osteoporosis treated with teriparatide (MATURITAS 2009; 63 S1: 90). 4. WASHINGTON, DC (USA), JUNE 10-13, The Endocrine Society, 91st Annual Meeting (ENDO 09): Impact of hypercalcemia on arterial blood pressure in postmenopausal women with primary hyperparathyroidism. 5. BARCELONA (SPAIN), 30 JUNE-3 JULY, European Society for Medical Oncology (ESMO) Conference, 12th World Congress on Gastrointestinal Cancer. Usefulness of robotic radiosurgery for local control of unresectable multiple liver metastases from colorectal cancer: preliminary results (ANN ONCOL 2009; 20 S7: 94). 6. BUDAPEST (HUNGARY), SEPTEMBER 3-4, nd European Congress on the Aging Male. a. Arterial blood pressure and its relationship with serum calcium and PTH in elderly men with primary hyperparathyroidism (AGING MALE 2009; 12: 144). b. Improvement of hypoxemia according to weight reduction in patients with extremely severe obesity (AGING MALE 2009; 12: 147). 7. BERLIN (GERMANY), SEPTEMBER, Joint ECCO 15-34th ESMO Multidisciplinary Congress: a. Robotic radiosurgery in the local control of unresectable liver metastases in patients with colorectal cancer. Preliminary results (EUR J CANCER 2009; 7 S2: 330). b. Preoperative serum CA 15-3 and CEA in women with breast cancer and their relationship with relapse of the disease (EUR J CANCER 2009; 7 S3: 18). c. Risk factors for breast cancer in elderly women. Retrospective analysis of 206 patients (EUR J CANCER 2009; 7 S2: 217). 8. ST. GALLEN (SWITZERLAND), DECEMBER 2-4, st International Colorectal Congress: Benign Colorectal Diseases: a. Conservative treatment of acute diverticulitis. b. Treatment of iatrogenic anal fistula with anal plug and mucosal flap: initial experience and outcome BERLIN (GERMANY) APRIL, th European Breast Cancer Conference (EBCC 6): a. Comparative study of long-term morbidity in patients with breast cancer after sentinel lymph node biopsy and axillary sampling versus axillary dissection (EUR J CANCER SUPPL 2008; 6: 151). b. Serum tumor markers CEA and CA 15-3, hormone receptor rate and MIB-1 score and their relationship in elderly women with breast cancer (EUR J CANCER SUPPL 2008; 6: 182). 2. NEW YORK, NY (USA) MAY, The New York Academy of Sciences, Meeting on Integrative physiology: a. Osteocalcin and bone specific alkaline phosphatase in healthy subjects with osteopenia and patients with insulin-dependent diabetes mellitus (ANN N Y ACAD SCI 2009; 1173: E64). b. Changes of bone formation markers osteocalcin and bone specific alkaline phosphatase in postmenopausal women with osteoporosis (ANN N Y ACAD SCI 2009; 1173: E60). 3. SAN FRANCISCO, CA (USA) JUNE, The Endocrine Society, 90th Annual Meeting (ENDO 08): 9

10 a. Soluble E-selectin and von Willebrand factor changes in patients with primary hyperparathyroidsm before and after parathyroidectomy (IN VIVO 2011; 25: 279). b. Relationship between arterial blood pressure, serum calcium and PTH in patients with primary hyperparathyroidism according to age and gender (p. 474). 4. DEN HAAG (THE NETHERLANDS)10-12 SEPTEMBER, European Society of Surgical Oncology (ESSO), 14 th Cancer Congress a. Usefulness of harmonic scalpel in patients with breast cancer undergoing axillary dissection. A casecontrol study (EUR J SURG ONCOL 2008; 34: 1007). b. Frozen-section examination and fine-needle aspiration cytology in patients with solitary thyroid nodules (EUR J SURG ONCOL 2008; 34: 1061). 5. KOS (GREECE) OCTOBER, th International Conference of Anticancer Research. Malignancy-related hypercalcemia: pathophysiology and treatment (ANTICANCER RES 2008; 28: 3390) WASHINGTON, DC (USA) MARCH 15-18, Society of Surgical Oncology (SSO), 60th Cancer Symposium: a. Usefulness of sestamibi scintimammography, axillary ultrasonography and FNA cytology in reducing the number of sentinel node procedures in patients with breast cancer (ANN SURG ONCOL 2007; 14: 86). b. Fine needle aspiration cytology and 99mTc-pertechnetate scintigraphy together in patients with differentiated thyroid carcinoma (ANN SURG ONCOL 2007; 14: 93). 2. NEW YORK, NY (USA) APRIL 25-28, nd Conference on skeletal biology and medicine. A New York Academy of Sciences and Mount Sinai School of Medicine jointly sponsored meeting: Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism. A prospective study. 3. TORONTO (CANADA) JUNE 2-6, The Endocrine Society, 89th Annual Meeting (ENDO 07): Estrogen therapy and risk of breast cancer in menopausal patients. A case-control study (MENOPAUSE 2010; 17: 524). 4. BARCELONA (SPAIN) SEPTEMBER, th European Cancer Conference (ECCO 14): Usefulness of imprint cytology and frozen section examination of the sentinel lymph node in patients with breast cancer (EUR J CANCER SUPPL 2007; 5: 205) SAN DIEGO, CA (USA) MARCH 23-26, Society of Surgical Oncology (SSO), 59th Cancer Symposium: a. Usefulness of high-resolution ultrasonography, fine-needle aspiration cytology, and flow cytometry in the diagnosis of primary and recurrent lymphoma (ANN SURG ONCOL 2006; 13 (S1): 76). b. Results and long-term follow up after unilateral adrenalectomy for cortisol secreting adrenal tumors (ANN SURG ONCOL 2006; 13 (S1): 77). 2. BOSTON (USA) JUNE 24-27, The Endocrine Society, 88th Annual Meeting (ENDO 06): a. Relationship between hormone receptor status and estrogen therapy in patients with breast cancer (ANTICANCER RES 2008; 28: 491). b. Advantages of minimally invasive radioguided parathyroidectmy in patients with solitary parathyroid adenoma. A prospective study (p. 359). 3. VENEZIA 30 NOVEMBER-2 DECEMBER, th Congress of the European Society of Surgical Oncology (ESSO 13): a. Long-term follow-up study of serum tumor markers CEA and CA 15-3 in patients with breast cancer. b. Accuracy of axillary node sampling in conjunction with sentinel node biopsy in assessing the axillary node status of patients with breast cancer. A prospective study. c. Role of combined ultrasonography and mammography in the detection of breast cancer in patients with breast complaints ATLANTA, GA (USA) MARCH 3-6, Society of Surgical Oncology (SSO), 58th Cancer Symposium: Quality-of-life of breast cancer women who underwent axillary node dissection by using ultrasound scissors. A prospective clinical study (ANN SURG ONCOL 2005; 12: 57). 2. SAN DIEGO, CA (USA) JUNE 4-7, The Endocrine Society, 87th Annual Meeting (ENDO 2005): 10

11 a. Intima-media thickness measurement in patients with primary hyperparathyroidism. A prospective casecontrol study and long-term follow-up (IN VIVO 2006; 20: 887). b. Endothelial markers in primary hyperparathyroidism (p. 673). 3. PARIS (FRANCE) 30 OCTOBER-3 NOVEMBER, th European Cancer Conference (ECCO 13): a. Risk of breast cancer associated with the use of hormone therapy. Retrospective analysis using a logistic regression model (EUR J CANCER SUPPL 2005; 3: 106). b. Relationship between hormone receptor rate, CEA, CA 15-3 and MIB-1 in patients with breast cancer recurrence (EUR J CANCER SUPPL 2005; 3: 108). c. Sentinel node biopsy and axillary node sampling in women with breast cancer undergoing breast conserving surgery. Preliminary results from a prospective study (EUR J CANCER SUPPL 2005; 3: 112). d. Immunohistochemical markers PCNA-LI and Ki-67, and DNA index in patients with parathyroid carcinoma (EUR J CANCER SUPPL 2005; 3: 316) NEW YORK (USA) MARCH 18-21, Society of Surgical Oncology (SSO), 57th Cancer Symposium: a. Different operative protocols for minimally invasive radioguided parathyroidectomy. A randomized prospective study (ANN SURG ONCOL 2004; 11: 103). b. Risk of malignancy in patients with incidentally discovered adrenal masses. Accuracy of CT-scan, MRI, norcholesterol scintigraphy, and image-guided FNA cytology (ANN SURG ONCOL 2004; 11: 104). 2. BUDAPEST (HUNGARY) 31 MARCH-3 APRIL, European Society of Surgical Oncology, 12th Cancer Congress (ESSO 12): a. DNA index, PCNA and Ki-67 activity in predicting biological behavior of parathyroid carcinomas. A retrospective study of 15 cases (EUR J SURG ONCOL 2004; 30: 192). b. Accuracy of ultrasound scan and 99mTc-sestamibi scintimammography for assessing axillary lymph node status in women with breast cancer undergoing curative surgery. A prospective study (EUR J SURG ONCOL 2004; 30: 136). 3. NEW ORLEANS, LA (USA) JUNE 16-19, The Endocrine Society, 86th Annual Meeting (ENDO 2004): a. Long-term outcome and quality of life after bilateral adrenalectomy in patients with Cushing s disease previously treated by transsphenoidal pituitary microsurgery (p. 565). b. Results of unilateral adrenalectomy in patients with aldosterone-producing adenoma. Long-term followup study and analysis of causes of persistent hypertension (AM SURG 2005; 71: 864). 4. LISBOA (PORTUGAL) 31 AUGUST-4 SEPTEMBER, th International Congress of Endocrinology (ICE 2004): a. Clinical and biochemical features of primary hyperparathyroidism in the elderly. A retrospective study in 139 patients who underwent parathyroidectomy (p. 271). b. Long-term effects of cyproterone acetate, finasteride and spironolactone in patients with idiopathic hirsutism. A randomized prospective study (EXPERT REV PHARMACOECON OUTCOMES RES 2004; 4: 297) LYON (FRANCE) APRIL, th European Congress of Endocrinology: a. Clinical and biochemical features in pre- and postmenopausal women with primary hyperparathyroidism. Results from a multivariate analysis (p. 515). b. The relationship of nuclear DNA content AgNOR counts to clinical outcome in patients with parathyroid carcinoma (ENDOCR RELAT CANCER 2004; 11: 563). 2. OSAKA (JAPAN) JUNE 3-7, International Bone and Mineral Society (IBMS) & Japanese Society of Bone and Mineral Research (JSBMR), 1st Joint Meeting: a. Arterial blood pressure, serum calcium and parathyroid hormone levels in pre- and postmenopausal women with primary hyperparathyroidism (BONE 2003; 32 S1: 112). b. Primary hyperparathyroidism in male and female patients: clinical, biochemical and pathological features in a population of 278 patients who underwent surgery (BONE 2003; 32 S1: 113). 3. PHILADELPHIA, PA (USA) JUNE 19-22, The Endocrine Society, 85th Annual Meeting (ENDO 2003): Role of CT scan, magnetic resonance imaging and I-123 metaiodobenzylguanidine scintigraphy for diagnostic localization of pheochromocytoma. A prospective study (NUCL MED COMMUN 2006; 27: 583). 11

12 4. COPENHAGEN (DENMARK) SEPTEMBER, th European Cancer Conference (ECCO 12): a. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pt1-2 breast cancer (EUR J CANCER SUPPL 2003; 39 S1: 127). b. 99mTc-sestamibi scintigraphy in axillary lymph node metastases detection in patients with primary breast cancer undergoing curative surgery (EUR J CANCER SUPPL 2003; 39 S1: 118) PARIS (FRANCE) 9-12 FEBRUARY, th International Symposium on Preventive Oncology: a. Primary hyperparathyroidism due to parathyroid tumors: how the disease has changed. Analysis of results in 335 patients who underwent surgery during the last 20 years (CANCER DETECT PREV 2002; 26 S1: 159). b. Role of 99mTc-sestamibi scintimammography in reducing the number of breast biopsies in patients with mammograms suggesting breast cancer (CANCER DETECT PREV 2002; 26 S1: 153). 2. LILLE (FRANCE) APRIL, European Society of Surgical Oncology, 11th Cancer Congress (ESSO 11): a. Accuracy of fine-needle aspiration cytology, CT-scan and MRI in patients with incidentally discovered adrenal masses (EUR J SURG ONCOL 2002; 28: 315). b. Relationship of 99mTc-uptake with prognostic factors of breast cancer, and causes of false negative results of scintimammography. Multivariate analysis using a logistic regression model (EUR J SURG ONCOL 2002; 28: 335) 3. DENVER, CO (USA) MARCH 14-17, Society of Surgical Oncology (SSO), 55th Cancer Symposium: Predictive factors of breast cancer risk in women. Univariate and multivariate analysis using a logistic regression model. A case-control study (ANN SURG ONCOL 2002; 9 S1: 59). 4. SAN FRANCISCO, CA (USA) JUNE 19-22, The Endocrine Society, 84th Annual Meeting (ENDO 2002): a. Improved sensitivity of localizing studies has reduced the hospital stay of patients who underwent parathyroidectomy for primary hyperparathyroidism (p. 452). b. Accuracy of thyroid scintigraphy, fine-needle aspiration cytology and frozen section examination in nontoxic solitary thyroid nodules. Comparative study in 657 patients who underwent thyroidectomy (p. 278). 5. HERSONISSOS (GREECE) OCTOBER, th International Congress of Advanced in Oncology: Usefulness of serum tumor markers CEA and CA 15-3 in patients with breast cancer. A long-term follow-up study (INTERN J MOL MED 2002; 10 S1: 40). 6. PARIS (FRANCE) 2 DECEMBER The Endocrine Aspects of Aging: Genes, Hormones and Lifestyle: Primary hyperparathyroidsm in the elderly. Does the disease differ in respect of younger patients? WASHINGTON, DC (USA) MARCH 15-18, Society of Surgical Oncology (SSO), 54th Cancer Symposium: Predictive value of different prognostic factors in breast cancer recurrence. Univariate and multivariate analysis (ANTICANCER RES 2001; 21: 4105). 2. MADRID (SPAIN) 5-10 JUNE, International Bone and Mineral Society (IBMS) & European Calcified Tissue International (ECTI), 1st Joint Meeting: a. Usefulness of 99mTc-sestamibi subtraction scintigraphy and spiral CT in parathyroid adenomas localization. Analysis of results in patients who underwent successful parathyroidectomy (BONE 2001; 28 S1: 114). b. Femoral and lumbar spine BMD changes in patients with primary hyperparathyroidism. Different improvement following successful parathyroidectomy in male and female patients (BONE 2001; 28 S1: 113). 3. DENVER, CO (USA) JUNE 20-23, The Endocrine Society, 83rd Annual Meeting (ENDO 2001): a. Usefulness of neck ultrasonography and sestamibi scintigraphy in patients with primary hyperparathyroidism and nontoxic thyroid nodules (ENDOCR RELAT CANCER 2003; 10: 419). b. Effects of cyproterone acetate, finasteride, and spironolactone in patients with idiopathic hirsutism. Shortand long-term results (FERTIL STERIL 2003; 79: 942). 4. LISBOA (PORTUGAL) OCTOBER, th European Cancer Conference (ECCO 11): a. Fine-needle aspiration cytology and frozen-section examination in pre- and intraoperative diagnosis of thyroid cancer (EUR J CANCER 2001; 37 S6: 109). b. Risk factors for breast cancer in women residing in an urban area of the Northwest of Italy (EUR J CANCER 2001; 37 S6: 182). 12

13 GRONINGEN (THE NETHERLANDS) 5-8 APRIL, European Society of Surgical Oncology, 10th Cancer Congress (ESSO 10): a. Usefulness of 99m-Tc-sestamibi scintigraphy in breast cancer. Results of a multicentric study in 239 patients. (EUR J SURG ONCOL 2000; 26: 260). b. Does sensitivity of tumor markers CEA and CA 15-3 significantly correlate with any preoperative parameters in breast cancer patients with recurrence? (EUR J SURG ONCOL 2000; 26: 264). 2. TAMPERE (FINLAND) 6-10 MAY, Calcified Tissue International, 27th European Symposium: Short- and long-term changes in bone mineral density following parathyroidectomy in male and female patients with primary hyperparathyroidism (CALCIF TISSUE INT 2000; 66 S1: 97). 3. TORONTO (CANADA) JUNE 21-24, The Endocrine Society, 82nd Annual Meeting (ENDO 2000): The effects of serum calcium and serum PTH on blood pressure in patients with primary hyperparathyroidism. Population-based study in 194 patients undergoing parathyroidectomy (EUR J ENDOCRINOL 2002; 146: 643). 4. WASHINGTON, DC (USA) 3/11/2000. European Association of Cancer Education & American Association of Cancer Education. 1st Joint Meeting: Can patients' information of new breast imaging techniques reduce the number of unnecessary breast biopsies? Usefulness of 99mTc-sestamibi scintimammography and factors affecting incorrect results (J CANCER EDUCATION 2000; 15: 16) ORLANDO, FL (USA) MARCH 4-7, Society of Surgical Oncology (SSO), 52nd Cancer Symposium: Breast cancer detection with 99mTc-sestamibi scintigraphy, mammography, and FNA cytology. Comparative study in 64 surgically treated patients (ANN SURG ONCOL 1999; 6: 568). 2. SAN DIEGO, CA (USA) JUNE 12-15, The Endocrine Society, 81st Annual Meeting (ENDO 1999): a. Noninvasive adrenal imaging in primary aldosteronism. Comparison of scintigraphy and CT-scan results in 49 surgically-treated patients (NUCL MED COMMUN 2003; 24: 683). b. Role of CT-scanning, MRI, and radiocholesterol scintigraphy as noninvasive adrenal imaging in Cushing's syndrome. Clinico-pathological and radiological correlations in 67 patients undergoing adrenalectomy (NUCL MED COMMUN 2002; 23: 469) CINCINNATI, OH (USA) SEPTEMBER 10-14, Nineteen Annual Meeting of the American Society for Bone and Mineral Research (ASMBR): Changes in bone mineral density following parathyroidectomy in primary hyperparathyroidism (J BONE MINER RES 1998; 12 S1: 232). 2. SAN DIEGO, CA (USA) MARCH 25-29, Society of Surgical Oncology (SSO), 51 st Cancer Symposium: Are breast complaints really related to breast cancer? Results from a retrospective study in 2,561 patients symptomatic patients observed during a 14-year period (BIOMED PHARMACOTHER 2002; 56: 88). 3. NEW ORLEANS, LA (USA) JUNE 24-27, The Endocrine Society, 80 th Annual Meeting (ENDO 98): a. Usefulness of technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography as noninvasive localization techniques in primary hyperparathyroidism (EUR J ENDOCRINOL 2000; 143: 755). b. Fine-needle aspiration biopsy in primary adrenal tumors. Clinical radiological and histological correlations (CANCER 2001; 93: 323). 4. FIRENZE 29 SETTEMBRE-1 OTTOBRE, st European Breast Cancer Conference (EBCC 1): Technetium-99m-sestamibi scintigraphy in suspected breast cancer. Radiologic and histologic correlations in 43 surgically treated patients (EUR J CANCER 1998; 34 S5: 76). 5. SAN FRANCISCO, CA (USA) DECEMBER 1-6, Second Joint Meeting of The American Society for Bone and Mineral Research (ASBMR) and The International Bone and Mineral Society (IBMS): a. Primary hyperparathyroidism in the nineties. How has it changed? (BONE 1998; 23 S1: 354). b. Preoperative localization studies with 201 Tl/ 99m Tc and 99m Tc-sestamibi scintigraphy, ultrasound and CTscanning in primary hyperparathyroidism (BONE 1998; 23 S1: 355). 13

14 RELAZIONI SU INVITO A CONGRESSI NAZIONALI ( ): 1. Milano 6/5/1997: XI Congresso Nazionale Società Italiana Fisiopatologia Chirurgica. Feocromocitoma. 2. S. Felice Circeo (LT) 27/6/1997: XXI Congresso Nazionale Società Italiana Oncologia Chirurgica. Locally invasive thyroid cancer. Our experience in 29 surgically treated patients. 3. Firenze 19/9/1997: XVII Congresso Nazionale Società Italiana di Endocrinochirurgia. Il carcinoma delle paratiroidi. 4. Bari 4/5/1998: XII Congresso Nazionale Società Italiana Fisiopatologia Chirurgica. Fisiopatologia della sindrome di Cushing. 5. Roma 26/11/1998: XVIII Congresso Nazionale Società Italiana di Endocrinochirurgia. Iperparatiroidismo primitivo persistente e ricorrente: strategie diagnostico-terapeutiche. 6. Pisa 22/9/1998: XXII Giornate Endocrionologiche Pisane. Narrow gauge needle aspiration cytology as diagnostic approach to adrenal masses. 7. Palermo 3/7/1999: Chirurgia tiroide e paratiroidi oggi. Indagini strumentali nell iperparatiroidismo 8. Padova 5/5/2000: Patologia benigna della mammella. Il dolore mammario, psicologia e clinica. 9. Castiglione della Pescaia (GR) 19/4/2001: Giornate Politematiche di Specialità Chirurgiche. Chirurgia videoassistita delle paratiroidi. 10. Genova 12/5/2001: La Day Surgery: realtà, problemi e prospettive. Day surgery e chirurgia delle paratiroidi 11. Conegliano (TV) 18/5/2001: Attualità in Endocrinochirurgia. Il morbo di Cushing. 12. Palermo 14/9/2001: XXI Congresso Nazionale Società Italiana di Endocrinochirurgia. Chirurgia miniinvasiva radioguidata delle paratiroidi. 13. Mestre (VE) 30/11/2001: VI Congresso Nazionale Società Italiana di Chirurgia Ambulatoriale e di Day Surgery. Chirurgia mini-invasiva nell iperparatiroidismo. 14. Vicenza 4/5/2002: L iperparatiroidismo primitivo. La terapia chirurgica dell iperparatiroidismo 15. Riva del Garda (TN) 24/5/2003: Attualità in tema di patologie tiroidee. Malattia di Basedow. 16. Catania 8/11/2003: IV Congresso Nazionale, Gruppo Italiano per lo Studio della Chirurgia Radioguidata e dell Immunoscintigrafia. La chirurgia radioguidata delle paratiroidi. 17. Bressanone (BZ) 15/10/2004: Chirurgia mini-invasiva nell iperparatiroidismo primitivo 18. Roma 19/10/2004: 106 Congresso Nazionale Società Italiana di Chirurgia. Comunicazione Chirurgo- Patologo in chirurgia oncologica: il carcinoma mammario. 19. Genova 12/11/2004: XXIV Congresso Nazionale Società Italiana di Endocrinochirurgia & European Joint Meeting of Endocrine Surgery: Radio-guided parathyroidectomy. 20. Priverno (LT) 21/5/2005: XIX Congresso Nazionale Società Italiana Fisiopatologia Chirurgica. Trattamento del nodulo tiroideo autonomo. 21. Cagliari 11/10/2005: 107 Congresso Nazionale Società Italiana di chirurgia. La linfectomia cervicale e sue complicanze nel trattamento dei carcinomi tiroidei differenziati. 22. Foggia 24/11/2005: XXV Congresso Nazionale Società Italiana di Endocrinochirurgia. Lesioni non palpabili e cancro della mammella: diagnostica per immagini e FNA eco-guidato. PEER REVIEWER su invito di riviste internazionali tra cui: 1. Acta Biotheoretica (ISSN: ) 2. Breast (ISSN: ) 3. BMC Endocrine disorders (ISSN: ) 4. British Journal of Cancer (ISSN: ) 5. Chemotherapy (ISBN: ) 6. Clinical Endocrinology (ISSN: ) 7. Clinical Medicine & Research (ISSN: ) 8. Endocrine (ISBN: X) 9. European Journal of Cancer (ISSN: ) 10. European Journal of Obstetrics & Gynecology (ISSN: ) 11. European Journal of Surgical Oncology (ISSN: ) 12. Gynecologic Oncology (ISSN: ) 13. Human Immunology (ISSN: ) 14. Indian Journal of Medical Sciences (ISSN: ) 15. Journal of Clinical Endocrinology and Metabolism (ISSN: X) 14

15 16. Journal of Internal Medicine (ISBN: ) 17. Journal of Postgraduate Medicine (ISSN: ) 18. Journal of Research in Medical Sciences (ISSN: ) 19. Journal of the American Board of Family Practice (ISSN: ) 20. Journal of the American College of Nutrition (ISSN: ) 21. Langenbeck s Archives of Surgery (ISSN: ) 22. Medical Practice and Reviews (ISSN: 2I ) 23. Saudi Medical Journal (ISSN: ) 24. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques (ISSN: ) 25. Thyroid (ISSN: ) 26. Tumor Biology (ISSN: ) 27. Tumori (ISSN: ) 28. Updates in Surgery (ISSN: X) 29. World Journal of Surgical Oncology (ISSN: ) 30. Yonsei Medical Journal (ISSN: ) COMPONENTE DI INTERNATIONAL EDITORIAL BOARD: INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, Athens, Greece. PUBBLICAZIONI SCIENTIFICHE (aggiornate al 30/06/2013) Sul sito ministeriale (MIUR) U-GOV sono riportate 538 pubblicazioni di cui: ARTICOLI SU RIVISTA: 235 ABSTRACT SU RIVISTA: 109 CAPITOLI DI LIBRO: 107 MONOGRAFIE: 10 ABSTRACT DI CONGRESSI: 77 PUBBLICAZIONI CON IMPACT FACTOR = = 289 IMPACT FACTOR TOTALE = = (ISI Web of Knowledge 2011) Author h-index = 23, Sum of Times Cited = 1526 (Scopus accessed 30/12/2012) h-index = 23 LINKS E BANCHE DATI: rch&sid=w13636ao7j4cdjgfpnc&preferencessaved=

16 SOCIETA' SCIENTIFICHE E GRUPPI DI STUDIO INTERNAZIONALI DI APPARTENENZA: 1. Collaborative Group on Epidemiological Studies of Female Cancers (Oxford, UK), dal European Society of Breast Cancer Specialists (EUSOMA), dal 2008: 3. European Society of Surgical Oncology (ESSO), Brussels (B), dal 2007: 4. Scientific Advisory Board, International Institute of Anticancer Research (IIAR), Athens (GR), dal The Endocrine Society, Bethesda, MA (USA), dal 1996: 6. The New York Academy of Sciences (NYAS), New York, NY (USA), dal 2000: 7. European Society for Medical Oncology (ESMO) Lugano (CH), dal 2008: 8. The Science Advisory Board, Arlington, VA (USA): 9. Società Italiana di Chirurgia (SIC) Roma, dal 1990: Società Italiana di Endocrinochirurgia (SIEC) Napoli, dal 1986: PRINCIPALI CAMPI DI RICERCA E PROFESSIONALI: Cancro e tumori benigni della mammella, Epidemiologia delle neoplasie mammarie, Iperparatiroidismo primitivo, Malattie e neoplasie del surrene, Tireopatie di interesse chirurgico. INTERESSI EXTRA-PROFESSIONALI: Musica, arte contemporanea, letteratura anglosassone, vela, sci. 16